An interventional study of Fasting in Lymphoma, Cancer and Fasting, sponsored by University of Oslo. Recruiting at 1 site in Norway. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by University of Oslo · Not applicable, Interventional, and Supportive care
The goal of this randomized controlled parallel group trial is to examine if fasting before and after chemotherapy is safe, feasible and acceptable. The study population will include patients with either Hodgkin lymphoma or Diffuse Large B Cell Lymphoma.
The main questions aimed to answer are:
Whether fasting during chemotherapy is safe for patients, whether it is feasible to implement in a clinical setting, and whether patients find it acceptable.
We also want to examine a number of patient-reported outcome measures regarding health status and quality of life, such as dietary intake and adverse events from chemotherapy.
Researchers will compare fasting to standard treatment.
Participants will:
3,018 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
This study's planned enrollment of 40 is close to the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →University of Oslo is the lead sponsor of 177 studies on the registry; 24 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group will fast 24 hours before and 24 hours after chemotherapy for all treatment cycles (4-6 cycles).
Other: Fasting
This group will receive standard treatment, which include no fasting.
Fasting implies 0 kilojoule. Water ad libitum is permitted.
Safety, measured as 1) number of adverse events
To test whether fasting is safe. 1) Explored by investigating adverse events from intermittent water-only fasting
Time frame: 1 year
Safety, measured as 2) changes in body weight
To test whether fasting is safe. 2) by investigating changes in body weight throughout the treatment comparing the intervention and control groups.
Time frame: 1 year
Feasibility,- measured by 1) recruitment (attrition rate)
Whether fasting is feasible. Explored in order to determine whether a larger trial can be successfully conducted in a similar setting with lymphoma patients fasting during cancer treatment.
Time frame: 1 year
Feasibility,- measured as 2) compliance
Whether fasting is feasible. Explored in order to determine whether a larger trial can be successfully conducted in a similar setting with lymphoma patients fasting during cancer treatment.
Time frame: 1 year
Acceptability,- patient burden, acceptance and experience
Whether fasting is acceptable. Explored from a perspective of the participant, as the degree to which patients find the trial, its procedures, and its interventions agreeable, suitable, and satisfactory during chemotherapy treatment
Time frame: 1 year
Adverse events from chemotherapy
Adverse events including number of infections, graded according to Common Terminology Criteria for Adverse Events
Time frame: 1 year
Toxicity, including hematological toxicity and standard organ toxicity
Evaluation of toxicity, including hematological toxicity and other relevant organ toxicities with blood test and using computer tomography (CT) or fluoro-deoxy-glucose positron emission tomography computer tomography (FDG-PET-CT)
Time frame: 1 year
Health-Related Quality of Life
By using EORTC QLQ-C30 questionnaire
Time frame: 1 year
Nutritional impact symptoms
The linguistic and content validation of the translated and culturally adapted Patient Generated Subjective Global Assessment (PG-SGA) will be utilized for gathering data on nutritional impact symptoms
Time frame: 1 year
Dietary intake
Dietary intake 24 hours before and 24 hours after chemotherapy and the usual intake between chemotherapy cycles using food diary.
Time frame: 1 year
Weight loss, body mass index (BMI) and body compositon
Bioelectrical impedance (BIA) will be used to collect data to explore changes in body weight, BMI and body composition.
Time frame: 1 year
Unplanned readmissions and hospitalization
In terms of numbers of readmissions, unplanned out- or inpatient visits, and days in the hospital
Time frame: 1 year
Mechanistic aspects of fasting
To better understand nutrition and metabolism related to fasting and cancer, we want to examine various biomarkers related to glucose, amino acid and fat metabolism, and inflammation, such as e.g. glucose, insulin, amino acids, triglycerides, C-reactive protein (CRP).
Time frame: 1 year
Fasting and microbiota
We will analyze the gut microbiota to explore the effect of fasting on the gut microbiota. We will collect feces samples at start and end of treatment to characterize the microbiota using high throughput sequencing.
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.